Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: A multicenter retrospective chart review study

Oncologist

Volumn 19, Issue 9, 2014, Pages 930-936

  Strosberg, Jonathan R ^a   Benson, Al B ^b   Huynh, Lynn ^c   Duh, Mei Sheng ^c   Goldman, Jamie ^d   Sahai, Vaibhav ^b   Rademaker, Alfred W ^b   Kulke, Matthew H ^e  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c ANALYSIS GROUP   (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Above standard dose; Carcinoid syndrome symptoms; Diarrhea; Flushing; Neuroendocrine tumor; Somatostatin analogs

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CAPECITABINE; DOXORUBICIN; EVEROLIMUS; FLUOROURACIL; OCTREOTIDE; STREPTOZOCIN; SUNITINIB; TEMOZOLOMIDE;

ADULT; ARTICLE; CARCINOID SYNDROME; COMORBIDITY; DEMOGRAPHY; DIARRHEA; DRUG DOSE ESCALATION; EVALUATION AND FOLLOW UP; FATIGUE; FEMALE; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; MULTICENTER STUDY; NEUROENDOCRINE TUMOR; PAIN; RADIOGRAPHY; TUMOR GROWTH; WEIGHT REDUCTION; ADVERSE DRUG REACTION; AGED; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; MALIGNANT CARCINOID SYNDROME; NEUROENDOCRINE TUMORS; PATHOLOGY;

AGED; DIARRHEA; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MALE; MALIGNANT CARCINOID SYNDROME; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE;

EID: 84906976762     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0120     Document Type: Article

References (20)

1. Yao JC, Hassan M, Phan A et al. One hundred years after "carcinoid": Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26: 3063-3072.
2. Van der Lely AJ, de Herder WW. Carcinoid syndrome: Diagnosis and medical management. Arq Bras Endocrinol Metabol 2005;49:850-860.
3. Anthony L, Vinik AI. Evaluating the characteristics and the management of patients with neuroendocrine tumors receiving octreotide LAR during a 6-year period. Pancreas 2011;40:987-994.
4. Creutzfeldt W. Carcinoid tumors: Development of our knowledge. World J Surg 1996;20:126-131.
5. Rorstad O. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. J Surg Oncol 2005;89:151-160.
6. Strosberg JR. Systemic treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): Current approaches and future options. Endocr Pract 2014;20:1-30.
7. Phan AT. Metastatic pancreatic neuroendocrine tumors (pNET): Placing current findings into perspective. Cancer Treat Rev 2013;39:3-9.
8. Caplin M, Ruszniewski P, Pavel M et al. A randomized, double-blind, placebo-controlled study of lanreotide antiproliferative response in patients with gastroenteropancreatic neuroendocrine tumors (CLARINET). Presented at: European Cancer Congress; September 27-October 1, 2013; Amsterdam, Netherlands.
9. Rinke A, Müller HH, Schade-Brittinger C et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group. J Clin Oncol 2009;27:4656-4663.
10. Sandostatin LAR depot [prescribing information]. Basel, Switzerland: Novartis, 1988.
11. Anthony LB, Stafford S, Cronin M et al. Octreotide LAR doses used in clinical practice: Results from an internet survey and a clinical practice. J Clin Oncol 2004;22(suppl):4274a.
12. Xu Y, Shih YCT, Leary CC et al. Dosing patterns of octreotide LAR among elderly patients with neuroendocrine tumors: Analysis of the SEER-Medicare database. J Clin Oncol 2012;30(suppl):e14550a.
13. Strosberg JR, Bobiak S, Zornosa CC et al. Dosing patterns for octreotide LAR in neuroendocrine tumor (NET) patients: NCCN NET outcomes database. Presented at: American Society of Clinical Oncology annual meeting; May 31, 2013; Chicago, IL.
14. Chadha MK, Lombardo J, Mashtare T et al. High-dose octreotide acetate for management of gastroenteropancreatic neuroendocrine tumors. Anticancer Res 2009;29:4127-4130.
15. Ferolla P, Faggiano A, Grimaldi F et al. Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses. J Endocrinol Invest 2012;35:326-331.
16. Strosberg J, Weber J, Feldman M et al. Above-label doses of octreotide-LAR in patients with metastaticsmallintestinal carcinoidtumors. Gastrointest Cancer Res 2013;6:81-85.
17. Kunz PL, Reidy-Lagunes D, Anthony LB et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas 2013;42:557-577.
18. Kulke MH, Benson AB III, Bergsland E et al. Neuroendocrine tumors. J Natl Compr Canc Netw 2012;10:724-764.
19. Oberg K, Kvols L, Caplin M et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreaticsystem. Ann Oncol 2004;15: 966-973.
20. Strosberg JR, Fisher GA, Benson AB et al. Systemictreatment in unresectable metastatic well-differentiated carcinoid tumors: Consensus results from a modified Delphi process. Pancreas 2013;42: 397-404.